Serum sclerostin in vascular calcification in CKD: a meta-analysis
Vascular calcification (VC) is recognized as a predictor of all-cause and CVD mortality in chronic kidney disease (CKD). VC in CKD is possibly associated with serum sclerostin. The study systematically investigated the role of serum sclerostin in VC in CKD. Following the Preferred Reporting Items fo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2186151 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850187087080325120 |
|---|---|
| author | Yan Lin Liman Mao Siqi Chen Canxin Zhou |
| author_facet | Yan Lin Liman Mao Siqi Chen Canxin Zhou |
| author_sort | Yan Lin |
| collection | DOAJ |
| description | Vascular calcification (VC) is recognized as a predictor of all-cause and CVD mortality in chronic kidney disease (CKD). VC in CKD is possibly associated with serum sclerostin. The study systematically investigated the role of serum sclerostin in VC in CKD. Following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, a systematic search was performed of the PubMed, Cochrane Library, and EMBASE databases from inception to 11 November 2022, to identify relevant eligible studies. The data were retrieved, analyzed, and summarized. The hazard ratios (HRs) and odds ratios (ORs) with their corresponding confidence intervals (CIs) were derived and pooled. Thirteen reports (3125 patients) met the inclusion criteria and were included. Sclerostin was associated with the presence of VC (pooled OR = 2.75, 95%CI = 1.81–4.19, p < 0.01) and all-cause mortality (pooled HR = 1.22, 95%CI = 1.19–1.25, p < 0.01) among patients with CKD, but with a decreased risk of cardiovascular events (HR = 0.98, 95%CI = 0.97–1.00, p = 0.02). This meta-analysis suggests that serum sclerostin is associated with VC and all-cause mortality among patients with CKD. |
| format | Article |
| id | doaj-art-80f5afb76e7d459a95c5f4288df652c8 |
| institution | OA Journals |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-80f5afb76e7d459a95c5f4288df652c82025-08-20T02:16:11ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492023-12-0145110.1080/0886022X.2023.2186151Serum sclerostin in vascular calcification in CKD: a meta-analysisYan Lin0Liman Mao1Siqi Chen2Canxin Zhou3Department of Nephrology, The Affiliated People’s Hospital, Ningbo University, Ningbo, ChinaDepartment of Nephrology, The Affiliated People’s Hospital, Ningbo University, Ningbo, ChinaDepartment of Nephrology, The Affiliated People’s Hospital, Ningbo University, Ningbo, ChinaDepartment of Nephrology, The Affiliated People’s Hospital, Ningbo University, Ningbo, ChinaVascular calcification (VC) is recognized as a predictor of all-cause and CVD mortality in chronic kidney disease (CKD). VC in CKD is possibly associated with serum sclerostin. The study systematically investigated the role of serum sclerostin in VC in CKD. Following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, a systematic search was performed of the PubMed, Cochrane Library, and EMBASE databases from inception to 11 November 2022, to identify relevant eligible studies. The data were retrieved, analyzed, and summarized. The hazard ratios (HRs) and odds ratios (ORs) with their corresponding confidence intervals (CIs) were derived and pooled. Thirteen reports (3125 patients) met the inclusion criteria and were included. Sclerostin was associated with the presence of VC (pooled OR = 2.75, 95%CI = 1.81–4.19, p < 0.01) and all-cause mortality (pooled HR = 1.22, 95%CI = 1.19–1.25, p < 0.01) among patients with CKD, but with a decreased risk of cardiovascular events (HR = 0.98, 95%CI = 0.97–1.00, p = 0.02). This meta-analysis suggests that serum sclerostin is associated with VC and all-cause mortality among patients with CKD.https://www.tandfonline.com/doi/10.1080/0886022X.2023.2186151Cardiovascular eventschronic kidney diseasesclerostinserum sclerostinvascular calcification |
| spellingShingle | Yan Lin Liman Mao Siqi Chen Canxin Zhou Serum sclerostin in vascular calcification in CKD: a meta-analysis Renal Failure Cardiovascular events chronic kidney disease sclerostin serum sclerostin vascular calcification |
| title | Serum sclerostin in vascular calcification in CKD: a meta-analysis |
| title_full | Serum sclerostin in vascular calcification in CKD: a meta-analysis |
| title_fullStr | Serum sclerostin in vascular calcification in CKD: a meta-analysis |
| title_full_unstemmed | Serum sclerostin in vascular calcification in CKD: a meta-analysis |
| title_short | Serum sclerostin in vascular calcification in CKD: a meta-analysis |
| title_sort | serum sclerostin in vascular calcification in ckd a meta analysis |
| topic | Cardiovascular events chronic kidney disease sclerostin serum sclerostin vascular calcification |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2186151 |
| work_keys_str_mv | AT yanlin serumsclerostininvascularcalcificationinckdametaanalysis AT limanmao serumsclerostininvascularcalcificationinckdametaanalysis AT siqichen serumsclerostininvascularcalcificationinckdametaanalysis AT canxinzhou serumsclerostininvascularcalcificationinckdametaanalysis |